WHAT IS BIOMEDICAL RESEARCH?
Biomedical research focuses on the study of human physiology and the treatment or understanding of disease. Biomedical research is conducted by physicians or biomedical scientists, as well as biologists, chemists, physicists, and other medical and scientific professionals.
Some biomedical research involves clinical trials, which are phased studies using human volunteers. These trials are designed to answer questions about safety and efficacy related to biologics, devices, pharmaceuticals, new therapies or new ways of using known treatments. Trials are often conducted in small groups initially but expand in later stages once safety and efficacy are established. Most clinical trials are FDA regulated, but there are some exceptions.
WHY IS BIOMEDICAL RESEARCH IMPORTANT?
Research through the years has led to many important discoveries that have improved human lives for the better. Some examples are new medications, improved medical procedures, new or improved tests like ultrasounds, X-ray machines or genetic testing, vaccines, and ways to stop smoking.
WHAT IS SRI'S ROLE IN VA RESEARCH?
Salem Research Institute handles over 75 pre-clinical and clinical VA Research projects annually, in both pre- and post-award phases. SRI’s involvement in biomedical research at Salem VA Health Care System spans a wide range of activities. SRI administration cultivate scientific collaborations, identify research funding opportunities, assist in the development of and submit research grant applications and budgets, negotiate contractual terms with research sponsors, hire and manage research staff, purchase research supplies and equipment, facilitate travel to scientific conferences, manage research revenue and expenditures, and create research project financial reports. SRI administration also works closely with the Salem VA Research and Development Service to facilitate required research regulatory and safety processes and procedures enforced for all research taking place within the Salem VA Health Care System.
SRI employs research staff who play an active role in the execution of biomedical research. These employees work directly with VA Research Principal Investigators to fulfill the research scope of work, maintain appropriate research and regulatory documentation, and perform data collection, storage, analysis and interpretation.
Investigators
.jpg)
Francis Cannizzo, MD
Madalina Macrea, MD
Rena Courtney, PhD
Thomas Martin, MD
Devasmita Dev, MD
Jacob Mathew, MD
.jpg)
Dana Holohan, MD
Stephanie Nagy-Agren, MD
Ali Iranamesh, MD
Kris Ann Oursler, MD
Nabil Jarmukli, MD
Amitabh Parashar, MD
Venkateswara Kollipara, MD
Mamta Sapra, MD
Aliza Lee, DPM
Anjali Varma, MD
Katherine Luci, MD
Shikha Vasudeva, MD
Sponsors
Research Areas and Active Trials
Behavioral Health:
Cardiology:
-
Effects of Ziltivekimab Versus Placebo on Morbidity and Mortality in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation
-
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
-
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients (REDEFINE-HF)
Endocrinology:
-
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
-
A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism
-
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
Pain Management:
Renal:
-
A Phase 2b Dose-finding, Randomized, Placebo-controlled, Double-blind Study to Evaluate Efficacy and Safety of BAY 3283142 on Top of Standard of Care in Reducing Albuminuria in Patients With Chronic Kidney Disease
-
A Phase 3 Randomized Controlled Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type 2 Diabetes and Chronic Kidney Disease (REGEN-006)